The Russian government will consider registering next-in-class drugs based on data from the second phase of clinical trials (CT) as well as will implement other measures in order to avoid a shortage of drugs in domestic market this year, The Pharma Letter’s local correspondent reports.
In recent years, the number of clinical trials, conducted by foreign pharmaceutical companies in Russia has significantly decreased, which led to the reduction of the range of original drugs in the local market.
At the same time the possibility of registering next-in-class drugs based on the second phase of clinical trials, which is currently considered by the Russian government, according to analysts, will reduce the time it takes to bring a drug to market from 10-7 to 5-3 years.
